Milestone Pharmaceuticals Inc. MIST
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a cardio-renal-metabolic drug developer. Its lead program, CARDAMYST (etripamil) nasal spray, is in Phase 2 for Paroxysmal supraventricular tachycardia (PSVT).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| CARDAMYST (etripamil) nasal spray | PSVT | small molecule | Approved |
| etripamil nasal spray | Atrial fibrillation with rapid ventricular rate (AFib-RVR) | small molecule | Phase 2 |
Recent results and decisions
- Sep 3, 2026approval China's NMPA approves etripamil nasal spray for the treatment of PSVT in adults, marking the first regulatory approval of etripamil outside the United States.
China's National Medical Products Administration (NMPA) has approved etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT) in adults.
Filing - Sep 3, 2026met Phase 3 JX02002 study in China met its primary endpoint, demonstrating etripamil was significantly superior to placebo in converting PSVT to sinus rhythm within 30 minutes.
JX02002 met its primary endpoint, demonstrating that etripamil was significantly superior to placebo in converting PSVT to sinus rhythm within 30 minutes of treatment (hazard ratio = 3.002 [95% CI: 1.578, 5.711]; p = 0.0005).
Filing - Dec 12, 2025approval FDA approved CARDAMYST, the first self-administered nasal spray for PSVT, ahead of the Dec 13 PDUFA date; label supported by Phase 3 RAPID (64% vs 31% conversion within 30 minutes, p<0.001); US retail availability expected Q1 2026.
today announced that the U.S. Food and Drug Administration (FDA) approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults.
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.